Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Combination therapy with angiotensin-converting-enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) decreases proteinuria; however, its safety and effect on the progression of kidney disease are uncertain. Methods We provided losartan (at a dose of 100 mg per day) to patients with type 2 diabetes, a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 300, and an estimated glomerular filtration rate (GFR) of 30.0 to 89.9 ml per minute per 1.73 m(2) of body-surface area and then randomly assigned them to receive lisinopril (at a dose of 10 to 40 mg per day) or placebo. The primary end point was the first occurrence of a change in the estimated GFR (a decline of ≥ 30 ml per minute per 1.73 m(2) if the initial estimated GFR was ≥ 60 ml per minute per 1.73 m(2) or a decline of ≥ 50% if the initial estimated GFR was <60 ml per minute per 1.73 m(2)), end-stage renal disease (ESRD), or death. The secondary renal end point was the first occurrence of a decline in the estimated GFR or ESRD. Safety outcomes included mortality, hyperkalemia, and acute kidney injury. Results The study was stopped early owing to safety concerns. Among 1448 randomly assigned patients with a median follow-up of 2.2 years, there were 152 primary end-point events in the monotherapy group and 132 in the combination-therapy group (hazard ratio with combination therapy, 0.88; 95% confidence interval [CI], 0.70 to 1.12; P=0.30). A trend toward a benefit from combination therapy with respect to the secondary end point (hazard ratio, 0.78; 95% CI, 0.58 to 1.05; P=0.10) decreased with time (P=0.02 for nonproportionality). There was no benefit with respect to mortality (hazard ratio for death, 1.04; 95% CI, 0.73 to 1.49; P=0.75) or cardiovascular events. Combination therapy increased the risk of hyperkalemia (6.3 events per 100 person-years, vs. 2.6 events per 100 person-years with monotherapy; P<0.001) and acute kidney injury (12.2 vs. 6.7 events per 100 person-years, P<0.001). Conclusions Combination therapy with an ACE inhibitor and an ARB was associated with an increased risk of adverse events among patients with diabetic nephropathy. (Funded by the Cooperative Studies Program of the Department of Veterans Affairs Office of Research and Development; VA NEPHRON-D ClinicalTrials.gov number, NCT00555217.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Given that diastolic heart disease develops early in T2D and the renin-angiotensin-aldosterone system (RAAS) plays a critical role in the pathophysiology of HF, the use of an ACE inhibitor or ARBs could be considered early in the treatment of hypertension, before the diagnosis of HF.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [260]
In the citing paper
“Given that diastolic heart disease develops early in T2D and the renin-angiotensin-aldosterone system (RAAS) plays a critical role in the pathophysiology of HF, the use of an ACE inhibitor or ARBs could be considered early in the treatment of hypertension, before the diagnosis of HF.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [260]
In the citing paper
“Two clinical trials studied the combinations of ACE inhibitors and ARBs and found no benefits on CVD or CKD, and the medication combination had higher adverse event rates (hyperkalemia and/or AKI) (87,88).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [88]
In the citing paper
“Long-term outcome trials in patients with diabetes and CKD demonstrated no kidney or cardiovascular bene fi t of RAS blockade with combined therapy to block the RAS versus the single use of RAS inhibitors.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [85]
In the citing paper
“However, combination therapy was associated with a higher rate of hyperkalemia and AKI, 85,86”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [85]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Levey, A. S., Coresh, J., Bolton, K., Culleton, B. F., Harvey, K. S., Ikizler, T. A., Johnson, C. A., Kausz, A., Kimmel, P. L., Kusek, J. W., et al. (2002) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 11,633
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Telmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502
Mann, J. F., Schmieder, R. E., McQueen, M., Dyal, L., Schumacher, H., Pogue, J., Wang, X., Maggioni, A., Budaj, A., Chaithiraphan, S., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61236-2 · Cited by 1,589
Cardiorenal end points in a trial of aliskiren for type 2 diabetes
Parving, H.-H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Desai, A. S., Nicolaides, M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208799 · Cited by 1,319
Clinical Physiology of Acid-Base and Electrolyte Disorders
(1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-113-2-176_8 · Cited by 1,156
de Zeeuw, D., Remuzzi, G., Parving, H.-H., Keane, W. F., Zhang, Z., Shahinfar, S., Snapinn, S., Cooper, M. E., Mitch, W. E., & Brenner, B. M. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00653.x · Cited by 975
Ruggenenti, P., Perna, A., Gherardi, G., Garini, G., Zoccali, C., Salvadori, M., Scolari, F., Schena, F. P., & Remuzzi, G. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10363-x · Cited by 910
Research works printed but not linked: 2
- National Kidney Foundation, 2002, Am J Kidney Dis, 30, S1
- International Conference on Harmonisation, 1995, Fed Regist, 60, 11284
Cited by
Items 401–500 of 1,001
When should we start and stop ACEi/ARB in paediatric chronic kidney disease?
Chan, E. Y.-H., Ma, A. L.-T., & Tullus, K. (2020) · Pediatric Nephrology · doi:10.1007/s00467-020-04788-w · Cited by 30
Noshahr, Z. S., Ebrahimzadeh‐Bideskan, A., Hadjzadeh, M.-A.-R., Shafei, M. N., Salmani, H., Hosseinian, S., & Rad, A. K. (2021) · Biochimie · doi:10.1016/j.biochi.2021.03.011 · Cited by 31
Chazova, I. E., Михайловна, Ч. Н., Blinova, N. V., Belaya, Z. E., Danilov, N. M., Elfimova, E. M., Litvin, A. Y., Rozhinskaya, L. Y., Sviridenko, N. Y., Швецов, М. Ю., et al. (2023) · Eurasian heart journal · doi:10.38109/2225-1685-2023-1-6-65 · Cited by 34
Hyperkalemia in CKD: an overview of available therapeutic strategies
Costa, D., Patella, G., Provenzano, M., Ielapi, N., Faga, T., Zicarelli, M., Arturi, F., Coppolino, G., Bolignano, D., Sarro, G. D., et al. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1178140 · Cited by 37
Sarafidis, P. A., Memmos, E., Alexandrou, M. E., & Papagianni, A. A. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190306162658 · Cited by 31
Motrapu, M., Świderska, M. K., Aranda, I. M., Marschner, J. A., Lei, Y., Valenzuela, L. M., Fu, J., Lee, K., Angelotti, M. L., Antonelli, G., et al. (2020) · Journal of the American Society of Nephrology · doi:10.1681/asn.2019070703 · Cited by 30
Transdermal contraception and the renin-angiotensin-aldosterone system in premenopausal women
Odutayo, A., Cherney, D. Z. I., Miller, J., Ahmed, S. B., LAI, V. S., Dunn, S., Pun, N., Moineddin, R., & Hladunewich, M. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00602.2014 · Cited by 30
Curovic, V. R., Hansen, T. W., Eickhoff, M. K., von Scholten, B. J., Reinhard, H., Jacobsen, P. K., Persson, F., Parving, H., & Rossing, P. R. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1205-0 · Cited by 32
Calcium channel blocker in patients with chronic kidney disease
Ohno, S., Ishii, A., Yanagita, M., & Yokoi, H. (2021) · Clinical and Experimental Nephrology · doi:10.1007/s10157-021-02153-1 · Cited by 30
Vitamin D analogues to target residual proteinuria: potential impact on cardiorenal outcomes
Humalda, J. K., Goldsmith, D. J. A., Thadhani, R., & de Borst, M. H. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfu404 · Cited by 33
New options for the management of chronic hyperkalemia
Fried, L. F., Kovesdy, C. P., & Palmer, B. F. (2017) · Kidney International Supplements · doi:10.1016/j.kisu.2017.09.001 · Cited by 31
Self-citationKim, H. W., Lee, D. H., Lee, S. A., & Koh, G. (2015) · International Urology and Nephrology · doi:10.1007/s11255-015-1001-5 · Cited by 29
Hošková, L., Málek, I., Kautzner, J., Honsová, E., van Dokkum, R. P. E., Husková, Z., Vojtíšková, A., Jíchová, Š., Červenka, L., & Kopkan, L. (2014) · Hypertension Research · doi:10.1038/hr.2014.79 · Cited by 29
Bardoxolone methyl in type 2 diabetes and advanced chronic kidney disease.
Chertow, G. M., & de Zeeuw, D. (2014) · PubMed · doi:10.1056/nejmc1400872 · Cited by 18
Treatment and practical considerations of diabetic kidney disease
Bilen, Y., Almoushref, A., Alkwatli, K., Osman, O., Mehdi, A., & Sawaf, H. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1264497 · Cited by 29
Młynarska, E., Budny, E., Saar, M., Wojtanowska, E., Jankowska, J., Marciszuk, S., Mazur, M., Rysz, J., & Franczyk, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910429 · Cited by 31
Moratal, C., Laurain, A., Naïmi, M., Florin, T., Esnault, V. L. M., Neels, J. G., Chevalier, N., Chinetti, G., & Favrè, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22116009 · Cited by 29
Mallik, R., & Chowdhury, T. A. (2022) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188221081601 · Cited by 31
Tian, M., Shen, Y., Sun, Z.-L., & Zha, Y. (2015) · International Urology and Nephrology · doi:10.1007/s11255-015-0968-2 · Cited by 31
Pai, P., Muo, C., Sung, F., Ho, H.-C., & Lee, Y. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.04.096 · Cited by 29
Pandey, A., & Gaikwad, A. B. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.04.134 · Cited by 29
Exenatide and Renal Outcomes in Patients with Type 2 Diabetes and Diabetic Kidney Disease
Wang, X., Zhang, H., Zhang, Q., Guan, M., Sheng, S., Mo, W., Zou, M., Li, J., Bi, J., Tang, X., et al. (2020) · American Journal of Nephrology · doi:10.1159/000510255 · Cited by 29
Aspectos celulares y moleculares de la nefropatía diabética, rol del VEGF-A
Carranza, K., Verón, D., Cercado, A. G., Bautista, N., Pozo, W., Tufró, A., & Verón, D. (2015) · Nefrología · doi:10.1016/j.nefro.2015.05.013 · Cited by 36
Swiderski, J., Gadanec, L. K., Apostolopoulos, V., Moore, G. J., Kelaidonis, K., Matsoukas, J., & Zulli, A. (2023) · Biomolecules · doi:10.3390/biom13050787 · Cited by 27
Giubilato, S., Lucà, F., Abrignani, M. G., Gatto, L., Rao, C. M., Ingianni, N., Amico, F., Rossini, R., Caretta, G., Cornara, S., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12185989 · Cited by 33
Zhou, D., Zhou, T., Tang, S., Li, Q., Li, W., Gan, G., Li, M., & Qiu, C. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1354950 · Cited by 34
Grams, M. E., & Melamed, M. L. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-02684 · Cited by 30
Samson, S. L., Vellanki, P., Blonde, L., Hirsch, I. B., Hoang, T. D., Isaacs, S. D., Izuora, K. E., Wang, C. C. L., Ooi, C. P., Padilla, B. I., et al. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.01.006 · Cited by 34
Kowalski, A., Krikorian, A., & Lerma, E. V. (2014) · Europe PMC (PubMed Central) · Cited by 38
Thrombotic Microangiopathies with Rheumatologic Involvement
Babar, F., & Cohen, S. D. (2018) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2018.06.010 · Cited by 27
Bover, J., Ureña, P., Mateu, S., daSilva, I., Gràcia, S., Sánchez-Baya, M., Arana, C., de Arizón, L. F., Guirado, L., & Cozzolino, M. G. (2019) · Clinical Kidney Journal · doi:10.1093/ckj/sfz187 · Cited by 29
Increased indoleamine 2,3-dioxygenase activity in type 2 diabetic nephropathy
Zhang, Y., Ruan, Y., Zhang, P., & Wang, L. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.08.020 · Cited by 27
On behalf of the “Conservative Treatment of CKD” Study Group of the Italian Society of Nephrology, Bellizzi, V., Conte, G. L., Borrelli, S., Cupisti, A., Nicola, L. D., Iorio, B. R. D., Cabiddu, G., Mandreoli, M., Paoletti, E., et al. (2016) · Journal of Nephrology · doi:10.1007/s40620-016-0338-x · Cited by 29
Zheng, J., Jiang, Z., Chen, D., Wang, S., Zhao, W., & Li, L. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12934 · Cited by 27
Jigheh, Z. A., Haghjo, A. G., Argani, H., Roshangar, L., Rashtchizadeh, N., Sanajou, D., Ahmad, S. N. S., Rashedi, J., Dastmalchi, S., & Abbasi, M. M. (2018) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-018-0790-6 · Cited by 27
Konvalinka, A., Batruch, I., Tokár, T., Dimitromanolakis, A., Reid, S., Song, X., Pei, Y., Drabovich, A. P., Diamandis, E. P., Jurišica, I., et al. (2016) · Clinical Proteomics · doi:10.1186/s12014-016-9117-x · Cited by 28
Management of hypertension in patients with chronic kidney disease
Hamrahian, S. M. (2017) · Current Hypertension Reports · doi:10.1007/s11906-017-0739-9 · Cited by 26
Sato, A. (2015) · Hypertension Research · doi:10.1038/hr.2015.19 · Cited by 26
Haruhara, K., Suzuki, T., Wakui, H., Azushima, K., Kurotaki, D., Kawase, W., Uneda, K., Kobayashi, R., Ohki, K., Kinguchi, S., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.01.031 · Cited by 28
Cao, Z., Zhao, H., Fan, J., Shen, Y., Han, L., Jing, G., Zeng, X. L., Jin, X., Zhu, Z., Bian, Q., et al. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01304-5 · Cited by 28
The therapeutic effect of mesenchymal stem cells in diabetic kidney disease
Habiba, U. E., Khan, N., Greene, D. L., Shamim, S., & Umer, A. (2024) · Journal of Molecular Medicine · doi:10.1007/s00109-024-02432-w · Cited by 27
Pye, C., Elsherbiny, N. M., Ibrahim, A. S., Liou, G. I., Chadli, A., Al‐Shabrawey, M., & Elmarakby, A. A. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.05.004 · Cited by 26
Heinzel, A., Perco, P., Mayer, G. J., Oberbauer, R. W., Lukas, A., & Mayer, B. (2014) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2014.00037 · Cited by 26
An update of the blockade of the renin angiotensin aldosterone system in clinical practice
Márquez, D. F., Ruiz‐Hurtado, G., Ruilope, L. M., & Segura, J. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1079623 · Cited by 27
Nonsteroidal mineralocorticoid antagonists in diabetic kidney disease
Dojki, F. K., & Bakris, G. L. (2017) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000340 · Cited by 26
Should ACE inhibitors and ARBs be used in combination in children?
Stotter, B. R., & Ferguson, M. A. (2018) · Pediatric Nephrology · doi:10.1007/s00467-018-4046-8 · Cited by 29
Antifibrotic Roles of RAAS Blockers: Update
Zhang, Y., Yu, Y., & Yu, C. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-8871-2_33 · Cited by 30
Dual Renin-Angiotensin System Blockade for Nephroprotection: Still under Scrutiny
Gentile, G., Remuzzi, G., & Ruggenenti, P. L. (2014) · The Nephron journals/Nephron journals · doi:10.1159/000368331 · Cited by 25
Riccio, E., Capuano, I., Buonanno, P., Andreucci, M., Provenzano, M., Amicone, M., Rizzo, M., & Pisani, A. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.824095 · Cited by 31
Ma, Y., Deng, Y., Li, N., Dong, A., Li, H., Chen, S., Zhang, S., & Zhang, M. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.115768 · Cited by 29
Hypertension Management in Diabetic Kidney Disease
Patney, V., Whaley‐Connell, A. T., & Bakris, G. L. (2015) · Diabetes Spectrum · doi:10.2337/diaspect.28.3.175 · Cited by 28
Rutkowski, B., & Tylicki, L. (2015) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2014.10.026 · Cited by 26
Lai, X., Tong, D., Ai, X., Wu, J., Luo, Y., Zuo, F., Wei, Z., Li, Y., Huang, W., Wang, W., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-35148-2 · Cited by 26
Guo, F., Zhang, W., Su, J. Y., Xu, H., & Yang, H. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00049 · Cited by 28
Dual soluble epoxide hydrolase inhibitor/PPAR-γ agonist attenuates renal fibrosis
Stavniichuk, A., Khan, A. H., Yeboah, M. M., Chesnik, M. A., Jankiewicz, W. K., Hartmann, M., Blöcher, R., Kircher, T., Savchuk, О., Proschak, E., et al. (2020) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2020.106472 · Cited by 25
Have we reached the limits for the treatment of diabetic nephropathy?
Hajhosseiny, R., Khavandi, K., Jivraj, N. K., Mashayekhi, S., Goldsmith, D. J. A., & Malik, R. A. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.892580 · Cited by 29
Advances of Iron and Ferroptosis in Diabetic Kidney Disease
Chu, J., Wang, K., Lu, L., Zhao, H., Hu, J., Xiao, W., & Wu, Q. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.04.012 · Cited by 29
Georgianos, P. I., Vaios, V., Koufakis, T., & Liakopoulos, V. (2024) · Drugs · doi:10.1007/s40265-024-02091-8 · Cited by 27
Damman, K., ter Maaten, J. M., Mayne, K. J., Bolignano, D., Brown, E. M., da Costa, B. R., Dagre, A. G., Gansevoort, R. T., Gavina, C., Goette, A., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag098 · Cited by 33
Emerging therapies in immunoglobulin A nephropathy
Yeo, S. C., Liew, A., & Barratt, J. (2015) · Nephrology · doi:10.1111/nep.12527 · Cited by 24
Role of renin–angiotensin–aldosterone system inhibitors in heart failure and chronic kidney disease
Singhania, N., Bansal, S. K., Mohandas, S., Nimmatoori, D. P., Ejaz, A. A., & Singhania, G. (2020) · Drugs in Context · doi:10.7573/dic.2020-7-3 · Cited by 25
Rossing, P. R. (2022) · Kidney International Supplements · doi:10.1016/j.kisu.2021.11.005 · Cited by 25
Takenaka, T., Inoue, T., Ohno, Y., Miyazaki, T., Nishiyama, A., Ishii, N., & Suzuki, H. (2014) · Kidney & Blood Pressure Research · doi:10.1159/000355773 · Cited by 24
Resistant Hypertension and Chronic Kidney Disease: a Dangerous Liaison
Wolley, M. J., & Stowasser, M. (2016) · Current Hypertension Reports · doi:10.1007/s11906-016-0641-x · Cited by 25
Anguiano, L., Lei, Y., Devarapu, S. K., & Anders, H. (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfx219 · Cited by 26
Viazzi, F. C., Greco, E., Ceriello, A., Fioretto, P., Giorda, C. B., Guida, P., Russo, G. T., Cosmo, S. D., Pontremoli, R., & AMD-Annals Study Group (2018) · Kidney & Blood Pressure Research · doi:10.1159/000488255 · Cited by 26
ASIAN PACIFIC SOCIETY OF NEPHROLOGY CLINICAL PRACTICE GUIDELINE ON DIABETIC KIDNEY DISEASE
Liew, A., Bavanandan, S., Prasad, N., Wong, M. G., Chang, J. M., Eiam‐Ong, S., Hao, C., Lim, C. Y., Lim, S. K., Oh, K., et al. (2020) · Nephrology · doi:10.1111/nep.13785 · Cited by 24
New Treatment Options for Hyperkalemia in Patients with Chronic Kidney Disease
Esposito, P. B., Conti, N. E., Falqui, V., Cipriani, L., Picciotto, D., Costigliolo, F., Garibotto, G., Saio, M., & Viazzi, F. C. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082337 · Cited by 24
Association between hyperkalemia, RAASi non-adherence and outcomes in chronic kidney disease
Santoro, A., Perrone, V., Giacomini, E., Sangiorgi, D., Alessandrini, D., & Esposti, L. D. (2021) · Journal of Nephrology · doi:10.1007/s40620-021-01070-6 · Cited by 23
Potassium management with finerenone: Practical aspects
Wanner, C., Fioretto, P., Kovesdy, C. P., Małyszko, J., Pecoits‐Filho, R., Schnell, O., & Rossignol, P. (2022) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.360 · Cited by 25
Natale, P., Palmer, S. C., Navaneethan, S. D., Craig, J. C., & Strippoli, G. F. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006257.pub2 · Cited by 37
Has RAAS Blockade Reached Its Limits in the Treatment of Diabetic Nephropathy?
Majewski, C., & Bakris, G. L. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0713-y · Cited by 23
Hypertension in Chronic Kidney Disease – Role of Arterial Calcification and Impact on Treatment
Phan, O., Burnier, M., Wuerzner, G., & Nephrology, S. O. (2014) · European Cardiology Review · doi:10.15420/ecr.2014.9.2.115 · Cited by 25
Synergistic drug combinations prediction by integrating pharmacological data
Cheng-zhi, Z., & Yan, G. (2019) · Synthetic and Systems Biotechnology · doi:10.1016/j.synbio.2018.10.002 · Cited by 23
Ramos, A. M., Fernández‐Fernández, B., Pérez-Gómez, M. V., Julio, S. M. C., Sánchez-Niño, M. D., Sanz, A. B., Ruiz‐Ortega, M., & Ortíz, A. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1690450 · Cited by 25
Abdelhafiz, A. H. (2020) · Drugs & Aging · doi:10.1007/s40266-020-00773-y · Cited by 26
Shikata, K., Haneda, M., Ninomiya, T., Koya, D., Suzuki, Y., Suzuki, D., Ishida, H., Akai, H., Tomino, Y., Uzu, T., et al. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13339 · Cited by 24
Single versus dual blockade of the renin-angiotensin system in patients with IgA nephropathy
Lennartz, D. P., Seikrit, C., Wied, S., Fitzner, C., Eitner, F., Hilgers, R.-D., Rauen, T., & Floege, J. (2020) · Journal of Nephrology · doi:10.1007/s40620-020-00836-8 · Cited by 25
Using Mendelian randomization study to assess the renal effects of antihypertensive drugs
Zhao, J. V., & Schooling, C. M. (2021) · BMC Medicine · doi:10.1186/s12916-021-01951-4 · Cited by 25
Potential New Agents for the Management of Hyperkalemia
Packham, D., & Kosiborod, M. (2015) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-015-0130-7 · Cited by 23
Action plan for optimizing the design of clinical trials in chronic kidney disease
Perkovic, V., Craig, J. C., Chailimpamontree, W., Fox, C. S., García-García, G., Gharbi, M. B., Jardine, M., Okpechi, I. G., Pannu, N., Stengel, B., et al. (2017) · Kidney International Supplements · doi:10.1016/j.kisu.2017.07.009 · Cited by 25
The End of Dual Therapy with Renin–Angiotensin–Aldosterone System Blockade?
de Zeeuw, D. (2013) · New England Journal of Medicine · doi:10.1056/nejme1312286 · Cited by 25
Shetty, S., Suvarna, R., Awasthi, A., Bhojaraja, M. V., & Pappachan, J. M. (2025) · Diagnostics · doi:10.3390/diagnostics15080973 · Cited by 25
Capítulo 9 - Hipertensão Arterial na gestação
Malachias, M. V. B., Souza, W., Plavnik, F. L., Rodrigues, C., Brandão, A., Neves, M. F., Bortolotto, L. A., Franco, R., Poli‐de‐Figueiredo, C. E., Jardim, P., et al. (2016) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20160159 · Cited by 62
The Pillars for Renal Disease Treatment in Patients with Type 2 Diabetes
Kearney, J., & Gnudi, L. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051343 · Cited by 24
Aditya, N. R., & Mustofa, S. (2023) · MAJORITY · doi:10.59042/mj.v11i2.165 · Cited by 66
Imai, E., Ito, S., Haneda, M., Harada, A., Kobayashi, F., Yamasaki, T., Makino, H., & Chan, J. C. N. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv272 · Cited by 23
Kôyama, A., Fujita, T., Gejyo, F., Origasa, H., Isono, M., Kurumatani, H., Okada, K., Kanoh, H., Kiriyama, T., & Yamada, S. (2015) · BMC Nephrology · doi:10.1186/s12882-015-0130-5 · Cited by 22
Novel Therapies for Diabetic Kidney Disease: Storied Past and Forward Paths
Dieter, B. P., Alicic, R. Z., Meek, R. L., Anderberg, R. J., Cooney, S. K., & Tuttle, K. R. (2015) · Diabetes Spectrum · doi:10.2337/diaspect.28.3.167 · Cited by 22
Consensus document on the management of renal disease in HIV-infected patients.
Jl, G., Gutiérrez, F., Trullàs, J. C., Arazo, P., Arribas, J. R., Barril, G., Cervero, M., Cofán, F., Domingo, P., Estrada, V., et al. (2014) · PubMed · doi:10.3265/nefrologia.pre2014.jul.12674 · Cited by 25
Ruggenenti, P. L., Trillini, M., Barlovič, D. P., Cortinovis, M., Pisani, A., Parvanova, A. I., Iliev, I. P., Ruggiero, B., Rota, S., Aparicio, M., et al. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13639 · Cited by 24
Zheng, C., Wang, J., Chen, T.-T., Wu, Y., Wu, Y.-L., Lin, H.-T., Chiu, S.-P., Chang, T.-J., Zheng, J.-Q., Chu, N.-F., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-38991-z · Cited by 23
Zhang, S., Cao, M.-Q., Hou, Z., Gu, X.-Y., Chen, Y., Chen, L., Luo, Y., Chen, L.-W., Liu, D., Zhou, H.-Y., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.12.031 · Cited by 22
Mineralcorticoid receptor blockers in chronic kidney disease
Erraez, S., López-Mesa, M., & Gómez-Fernández, P. (2021) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2021.08.001 · Cited by 21
Mechanisms of Disease Reversal in Focal and Segmental Glomerulosclerosis
Yang, H., & Fogo, A. B. (2014) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2014.04.001 · Cited by 22
Once-Weekly Exenatide and Cardiovascular Outcomes in Type 2 Diabetes.
Holman, R. R., Bethel, M. A., & Hernandez, A. F. (2017) · PubMed · doi:10.1056/nejmc1714163 · Cited by 19
Xie, X.-X., Liu, P., Wan, F.-Y., Lin, S.-G., Zhong, W.-L., Yuan, Z.-K., Zou, J.-J., & Liu, L.-B. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.01.197 · Cited by 21
2023 Guideline for the management of hypertension in the elderly population in China
Hua, Q., Fan, L., Wang, Z., & Li, J. (2024) · 老年心脏病学杂志:英文版 · doi:10.26599/1671-5411.2024.06.001 · Cited by 23
Cardiorenal Protection in Diabetic Kidney Disease
Lee, J. F., Berzan, E., Sridhar, V. S., Odutayo, A., & Cherney, D. Z. I. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.987 · Cited by 23
Exploring molecular targets in diabetic kidney disease
Maruno, S., Tanaka, T., & Nangaku, M. (2022) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.21.251 · Cited by 24
Metadata
- Authors
- Fried, L. F., Emanuele, N., Zhang, J. H., Brophy, M., Conner, T. A., Duckworth, W., Leehey, D. J., McCullough, P. A., O'Connor, T., Palevsky, P. M., Reilly, R. F., Seliger, S. L., Warren, S. R., Watnick, S., Peduzzi, P., & Guarino, P.
- Affiliations
- Boston University (US)
- Loyola University Medical Center (US)
- VA Connecticut Healthcare System (US)
- University of New Mexico (US)
- University of Arizona (US)
- Ascension (US)
- University of Pittsburgh (US)
- VA North Texas Health Care System (US)
- University of Maryland, Baltimore (US)
- Portland VA Medical Center (US)
- Yale University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-11-14
- Volume
- 369
- Issue
- 20
- Pages
- 1892-1903
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2162368776
- Semantic Scholar
- 7e191f2ee9fe17b31623d78bf58b03d157e94654
- Cited by
- 1,169
- References
- 19
- Citations by year
- 2026: 32 · 2025: 56 · 2024: 67 · 2023: 95 · 2022: 75 · 2021: 102 · 2020: 89 · 2019: 105 · 2018: 88 · 2017: 98 · 2016: 104 · 2015: 123 · 2014: 122 · 2013: 9
- FWCI
- 90.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- diabetic nephropathy, losartan, lisinopril, ACE inhibitors, angiotensin receptor blockers, type 2 diabetes, estimated glomerular filtration rate decline, end-stage renal disease, albuminuria, hyperkalemia, acute kidney injury, drug safety, early trial termination, cardiovascular events, mortality, proteinuria, kidney disease progression
- MeSH terms
- Adult, Angiotensin-Converting Enzyme Inhibitors, Diabetic Nephropathies, Double-Blind Method, Drug Therapy, Combination, Female, Glomerular Filtration Rate, Humans, Kidney Failure, Chronic, Male, Middle Aged, Lisinopril, Losartan, Angiotensin II Type 1 Receptor Blockers, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.